CA2844150C - Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers - Google Patents

Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers Download PDF

Info

Publication number
CA2844150C
CA2844150C CA2844150A CA2844150A CA2844150C CA 2844150 C CA2844150 C CA 2844150C CA 2844150 A CA2844150 A CA 2844150A CA 2844150 A CA2844150 A CA 2844150A CA 2844150 C CA2844150 C CA 2844150C
Authority
CA
Canada
Prior art keywords
compound
alkoxy
nitro
treating
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2844150A
Other languages
English (en)
French (fr)
Other versions
CA2844150A1 (en
Inventor
L. Jackson Roberts
Venkataraman Amarnath
David G. Harrison
Annet Kirabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CA2844150A1 publication Critical patent/CA2844150A1/en
Application granted granted Critical
Publication of CA2844150C publication Critical patent/CA2844150C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2844150A 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers Active CA2844150C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
US61/506,848 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Publications (2)

Publication Number Publication Date
CA2844150A1 CA2844150A1 (en) 2013-01-17
CA2844150C true CA2844150C (en) 2019-09-03

Family

ID=47506934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2844150A Active CA2844150C (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Country Status (13)

Country Link
US (4) US10975033B2 (OSRAM)
EP (1) EP2731597B1 (OSRAM)
JP (1) JP6280033B2 (OSRAM)
KR (2) KR20140050661A (OSRAM)
CN (2) CN111494352A (OSRAM)
AU (1) AU2012281061B2 (OSRAM)
BR (1) BR112014000810A8 (OSRAM)
CA (1) CA2844150C (OSRAM)
ES (1) ES2970814T3 (OSRAM)
HU (1) HUE065757T2 (OSRAM)
MX (1) MX383365B (OSRAM)
PL (1) PL2731597T3 (OSRAM)
WO (1) WO2013010034A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US10166248B1 (en) 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
CN109689619A (zh) * 2016-07-06 2019-04-26 范德比尔特大学 使用反应性γ-酮醛的清除剂以延长细胞寿命和健康期限
MX393913B (es) * 2016-07-07 2025-03-24 Univ Vanderbilt Prevención y tratamiento de palpitación/fibrilación atrial con depuradores de gamma-cetoaldehídos.
AU2017324935B2 (en) * 2016-09-06 2021-10-21 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
PT3512863T (pt) * 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
JP7383285B2 (ja) * 2016-11-15 2023-11-20 ヴァンダービルト ユニバーシティー 肺高血圧症の治療及び予防における２－ヒドロキシベンジルアミンの使用
PL3615015T3 (pl) * 2017-04-27 2024-07-08 Vanderbilt University Zmiatacze gamma-ketoaldehydu do leczenia miażdżycy
CN111225666A (zh) * 2017-09-05 2020-06-02 Mti生物技术公司 用于治疗、预防或改善肝纤维化的γ-酮醛清除剂的组合物和使用方法
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
BR112022014876A2 (pt) * 2020-01-27 2022-12-13 Univ Vanderbilt Sequestradores de isolevuglandinas/isocetais que têm mitocôndria como alvo e usos dos mesmos
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
EP0839799A4 (en) 1995-05-19 1998-07-29 Kissei Pharmaceutical 2-HYDROXYPHENYLALKYLAMINE DERIVATIVES AND MAILLARD REACTION INHIBITORS
US6043259A (en) 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
WO2002036109A2 (en) * 2000-11-02 2002-05-10 University Of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) * 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
WO2009045145A1 (en) * 2007-10-05 2009-04-09 Index Pharmaceuticals Ab Novel compounds for the treatment or alleviation of edema, and methods for their use
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
JP6280033B2 (ja) 2018-02-14
PL2731597T3 (pl) 2024-04-29
HUE065757T2 (hu) 2024-06-28
KR20140050661A (ko) 2014-04-29
EP2731597A4 (en) 2015-04-08
US20250034093A1 (en) 2025-01-30
US10975033B2 (en) 2021-04-13
BR112014000810A8 (pt) 2022-11-29
EP2731597A2 (en) 2014-05-21
CN103796648B (zh) 2019-10-25
ES2970814T3 (es) 2024-05-30
US20210261508A1 (en) 2021-08-26
MX383365B (es) 2025-03-13
AU2012281061A1 (en) 2014-02-20
CN103796648A (zh) 2014-05-14
KR102050700B1 (ko) 2019-11-29
CN111494352A (zh) 2020-08-07
AU2012281061B2 (en) 2017-08-03
BR112014000810A2 (pt) 2017-06-13
JP2014524918A (ja) 2014-09-25
EP2731597C0 (en) 2023-12-20
MX2014000515A (es) 2014-03-27
EP2731597B1 (en) 2023-12-20
CA2844150A1 (en) 2013-01-17
WO2013010034A3 (en) 2013-03-28
US20250214939A1 (en) 2025-07-03
WO2013010034A2 (en) 2013-01-17
US20140256774A1 (en) 2014-09-11
KR20190069607A (ko) 2019-06-19

Similar Documents

Publication Publication Date Title
US20250214939A1 (en) Method for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
US20200062712A1 (en) Aldehyde trapping compounds and uses thereof
JP7655693B2 (ja) 神経変性障害を治療するための腸内微生物叢の制御
CN103037692B (zh) 用于抑制肌萎缩的方法
JP2019108391A (ja) 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
TW202337456A (zh) Ｇｍ２神經節苷脂症之治療
US8541435B2 (en) Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
JP2016210814A (ja) カルボン酸フェニルケトン化合物およびその薬学的使用
JP7466520B2 (ja) 神経変性障害を治療するためのスルホプロパン酸誘導体
HK1191859A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
HK1191859B (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
HK40023703A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
CN120040470A (zh) 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
JP6353159B2 (ja) Ｔｌｒ非依存性低分子アジュバント
JP2016204303A (ja) 抗健忘症用組成物
US20210369680A1 (en) Methods of treating diseases and disorders resulting from beta coronavirus infection
US20210171553A1 (en) Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
JP2025513458A (ja) ヨーグルト中の生体活性分子
WO2026099383A1 (en) Treatment of post-acute infection syndromes such as long covid and related symptoms
JP2008031066A (ja) 脱顆粒反応抑制剤
AU2021214090A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof
JP2022520222A (ja) ヒストンアセチルトランスフェラーゼモジュレーターおよび組成物ならびにそれらの使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707